United States

Developed Europe

Developed Rest of World

Emerging Markets

Total Internetional

Revenue by Geography

Revenue segments as reported by the company.

Primary Care

Specialty Care

Oncology

Pfizer CentreOne

Vaccines

Hospital

Internal Medicine

Rare Disease

Inflammation & Immunology

Pfizer Ignite

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, informational and administrative expenses

Research and development expenses

Amortization of intangible assets

Restructuring charges and certain acquisition-related costs

Other (income)/deductions

Acquired in-process research and development expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Pfizer

Sildenafil is a medication used to treat erectile dysfunction and pulmonary arterial hypertension. It is sold as the brand name Viagra among others.

Viagra

Atorvastatin is a member of the medication class known as statins, which are used primarily as a lipid-lowering agent and for prevention of events associated with cardiovascular disease. Like all statins, atorvastatin works by inhibiting HMG-CoA reductase, an enzyme found in liver tissue that plays a key role in production of cholesterol in the body. It is marketed under the trade name Lipitor among others

Lipitor

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pfizer exceeds $100B in revenue, eyes growth amid challenges

Pfizer's exceptional 2022 performance sets the stage for continued success in 2023.
Strategic investments in R&D and new product launches drive revenue growth expectations.
Challenges include transitioning from emergency status and revenue decline from COVID-related products.
Opportunities lie in increased adoption of combo vaccines and business development goals.

Pfizer reports solid Q1 results, eyes growth through innovation

Pfizer's Q1 performance was strong, driven by revenue growth and patient reach.
The company faces challenges in COVID franchise transition and stock performance.
Strategic acquisitions, new product launches, and market monitoring offer growth opportunities.
Pfizer's focus on innovation, trustworthiness, and commercial efficiency underpin its future success.

Pfizer reports Q2 growth amidst COVID uncertainties and therapeutic optimism

Pfizer's Q2 performance reflects growth in non-COVID revenues, strategic acquisitions, and a focus on new product launches. Challenges include uncertainties in revenue forecasts and operational adjustments post-acquisitions. Opportunities lie in therapeutic advancements and the potential of mRNA flu vaccines.

Pfizer reports strong Q3 performance, eyes growth in non-COVID products

Pfizer's Q3 performance showcased resilience in non-COVID product revenue growth, offsetting COVID-related declines. The company's strategic focus on global health impact and innovative acquisitions positions it for future growth. Challenges in the COVID product segment persist, but Pfizer remains optimistic about opportunities in new product launches and cancer treatment advancements.

Pfizer reports solid 2023 performance, eyes growth and cost savings

Pfizer's 2023 performance was strong despite challenges, with a focus on oncology, R&D, and cost savings. The company aims for revenue growth in 2024, emphasizing shareholder value and strategic priorities.

Pfizer reports robust Q1 earnings, eyes international growth and pipeline

Pfizer's Q1 2024 performance showcased strong revenue figures and strategic focus on non-COVID products and oncology, underlining the company's resilience and growth potential.
While facing challenges in adult market contraction and gross margin issues, Pfizer's strengths in pipeline innovation, product performance, and international market growth position it well for the future.
The company's opportunities lie in continued international expansion, consumer engagement initiatives, and upcoming pipeline advancements, signaling a path for sustained growth and innovation.

Pfizer reports strong Q2 earnings, raises guidance amid leadership changes

Pfizer's Q2 2024 earnings call reflects a robust performance, marked by revenue growth, leadership changes, and enhanced guidance. The company's strategic focus on oncology, vaccines, and product differentiation positions it for continued success. Challenges include maintaining market share post-generics and managing growth expectations for VYNDAQEL.

Pfizer reports robust Q3 earnings, eyes international market growth

Pfizer's Q3 earnings call highlighted strong performance, pipeline advancements, and a focus on shareholder value creation. Challenges include addressing the impact of IRA and maintaining growth in specific product lines. Opportunities lie in international market expansion and continued pipeline innovation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie

Dividend stocks benefit from falling interest rates as money managers shift to income-oriented equities with yields above the S&P 500.

Top 2 dividend stocks to buy for long-term gains

Pfizer stock is struggling to retake its 200-day line despite promising updates in cancer treatment. Is PFE stock now a sell?

Pfizer Lingers Near 11-Year Low Despite Promising Cancer Drug Updates — Is It A Sell?

Amgen

Alerian MLP ETF

Brookfield Asset Management

Blackrock Inc

Camden Property

Cisco Systems

Chevron

Enbridge

Enterprise Products Partners

Energy Transfer LP Unit

Coca-Cola

Lockheed Martin

Mid-America Apartment Communities

Main Street Capital

Global X MLP ETF

MPLX

Realty Income Corp

ONEOK

PepsiCo

Schwab US Dividend Equity ETF

TC Energy

Texas Instruments

Verizon

W. P. Carey

Warren Buffett once opined on how to live off of dividends in retirement. We discuss a simple way to follow his advice on this. We also share how to further enhance the yield on this portfolio while still generating strong dividend growth and keeping risk low.

A Simple $1 Million Passive Income Portfolio For Retirement

Bristol-Myers

Blackstone Secured Lending Fund

Kinder Morgan

Vici Properties

The Dividend Harvesting Portfolio generated over $100 of dividend income in May, with a return on invested capital of 14.14%. The portfolio's diversification helped stabilize market conditions, with a 1.45% growth in profitability despite market declines. Dividend income from various investment baskets, including equities, ETFs, REITs, CEFs, BDCs, and treasuries, contributes to portfolio growth.

Dividend Harvesting Portfolio Week 170: $17,000 Allocated, $1,515.47 In Projected Dividends

Pfizer's stock is currently trading below pre-pandemic levels, despite the record-breaking year it had in 2023 for FDA approvals and the significant acquisition of Seagen. Weak sentiment is likely explained by the significant risk of two best-selling products losing their exclusivity in 2026. Intrinsic value calculations suggest that the stock is 75% undervalued, meaning that the biggest risk is likely factored in.

Pfizer: Too Cheap To Miss Out

Moderna

Novavax

WASHINGTON — Government advisers Wednesday said it's time to update the recipe for the COVID-19 vaccines Americans will receive in the fall — targeting a version of the ever-evolving coronavirus called JN.1.

FDA advisers urge targeting JN.1 strain in fall's COVID vaccines

High-yield dividend stocks typically outperform the broader markets over long periods. AbbVie and Pfizer are two attractively priced high-yield dividend stocks worth considering right now.

2 High-Yield Dividend Stocks to Buy Right Now

Altria

Sell in May and go away? Maybe not this year, but be careful. Altria Group Inc. (NYSE MO) still owns 8% of Anheuser-Busch InBev S.A. (NYSE: BUD) after selling millions of shares.

My 3 Top Stocks to Buy in June

Pfizer has been trimming expenses as it adjusts to a decline in demand related to COVID-19. It recently announced a new cost-cutting plan that will save $1.5 billion in expenses.

Why Things Could Get Worse for Pfizer Stock Before They Get Better

British American Tobacco

Comcast

Gilead Sciences

AT&T

Finding good dividend stocks to buy amid market turbulence is essential in today's investing environment to maximize profits and minimize risks. These seven dividend stocks to buy have performance indicators that lead in a variety of industries.

7 Dividend Stocks to Invest In for a Lifetime of Income

Copa Hlds

Gerdau

Hafnia Ltd

Orange

United Microelectronics

The most obvious reason investors should buy high-yield dividend stocks is that they provide income. Non-dividend stocks do not provide income and only provide cash when sold.

The Income Investor's Dream Team: 7 Sturdy Dividend Stocks Yielding 6%

BHP Billiton

Innovative Industrial Properties

Philip Morris

Simon Property Group

Although seemingly most of the celebrated ideas on financial publications center on high-growth plays, investors should spare some thought toward high-yield dividend stocks. In particular, I'm referring to stable or relevant enterprises that offer considerable passive income.

7 High-Yield Dividend Stocks That Work While You Sleep

Sales of Pfizer's COVID-19-related products are down sharply, and so is the stock price. Pfizer stock has fallen about 24% over the past year.

1 Beaten-Down S&P 500 Dividend Stock to Buy in June and Hold For a Decade or Longer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 45th Annual Global Healthcare Conference on Monday, June 10, 2024 at 11:20 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning.

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Boeing

CVS Health

Tesla

Exxon Mobil

As you approach retirement, it's crucial to carefully consider your investment portfolio and make strategic decisions to safeguard your financial future. While some stocks may seem attractive, certain investments can pose significant risks to your retirement savings.

Retirement Roadblocks: 7 Stocks to Avoid as You Near the Finish Line

News for Pfizer Stock (PFE)